Chrysotoxine

Chrysotoxine is a dual inhibitor of Src/Akt. Chrysotoxine suppresses cancer stem cells (CSCs) phenotypes by down-regulating Src/Akt signaling. Chrysotoxine reduces cell viability and increases apoptosis level in H460 and H23 cells instead of non-tumor cell lines. Chrysotoxine shows rapid excretion and low bioavailability in rats. Chrysotoxine is used in cancer research[1][2].

Product Specifications

CAS Number

[156951-82-5]

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Akt; Apoptosis; Src

Type

Natural Products

Related Pathways

Apoptosis; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/chrysotoxine.html

Purity

99.52

Solubility

DMSO : 6.37 mg/mL (ultrasonic; warming)

Smiles

OC1=C(C=C(C=C1OC)CCC2=CC=C(C(OC)=C2)OC)OC

Molecular Formula

C18H22O5

Molecular Weight

318.36

Precautions

H315, H319

References & Citations

[1]Bhummaphan N, et al. Cancer Stem Cell-Suppressing Activity of Chrysotoxine, a Bibenzyl from Dendrobium pulchellum. J Pharmacol Exp Ther. 2018 Feb;364 (2) :332-346.|[2]Fan J, et al. Determination of chrysotoxine in rat plasma by liquid chromatography-tandem mass spectrometry and its application to a rat pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Sep 15;967:57-62.